Merck & Co., Inc. MRK Cash Flow

Merck & co., inc. (MRK)

CashFlow / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12	Dec'11	Dec'10	Dec'09	Dec'08	Dec'07
Cash Flows from Operating Activities
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
9,777	6,193	2,418	3,941	4,459	11,934	4,517	6,299	6,392	982	13,022	7,932	3,396
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation, Depletion and Amortization
3,652	4,519	4,676	5,471	6,375	6,691	6,988	6,978	7,427	7,381	2,576	1,631	1,988
Charge related to the settlement of worldwide Keytruda patent litigation
-	-	-	-625	0	0	0	-	-	-	-	-	-4,850
Charge for the acquisition of Peloton Therapeutics, Inc.
993	0	0	-	-	-	-	-	-	-	-	-	325
Intangible asset impairment charges
1,040	296	646	3,948	162	1,222	765	200	705	2,441	-	-	-
Charge for future payments related to collaboration license options
0	650	500	0	0	-	-	-	-	-	-	-	-
Provisional charge for one-time transition tax related to the enactment of U.S. tax legislation
0	0	5,347	0	0	-	-	-	-	-	-	-	-
Foreign currency devaluation related to Venezuela
-	-	-	-	-876	0	-140	-	-	-	-	-	-
Net charge related to the settlement of Vioxx shareholder class action litigation
-	-	-	-	680	0	-	-	-	-	-	-	-
Gain on divestiture of Merck Consumer Care business
-	-	-	-	-	11,209	0	0	-	-	-	-	-
Gain on AstraZeneca option exercise
-	-	-	-	-	741	0	0	136	443	3,163	2,223	-
Loss on extinguishment of debt
-	-	-	-	-	-628	0	0	-	-	-	-	-
Gain related to Merck/Schering-Plough partnership
-	-	-	-	-	-	-	-	-	-	7,530	-	0
Gain on disposition of interest in Merial Limited
-	-	-	-	-	-	-	-	-	-	-	-	0
Equity income from affiliates
-	-	-	-	205	257	404	642	610	587	2,235	2,561	2,976
Dividends and distributions from equity method affiliates
-	-	-	-	50	185	237	291	216	324	1,724	4,290	2,485
Deferred income taxes
-556	-509	-2,621	-1,521	-764	-2,600	-330	669	-1,537	-1,092	1,821	530	-1,781
Share-based Payment Arrangement, Noncash Expense
417	348	312	300	299	278	276	335	369	509	415	348	330
Other
-184	-978	-190	-213	-874	-34	-259	-28	-323	-377	535	608	-186
Net changes in assets and liabilities:
Accounts receivable
-294	418	-297	619	480	554	-436	-349	1,168	1,089	-165	889	-290
Inventories
508	911	145	-206	-805	-79	365	482	678	-1,990	-1,211	452	-40
Trade accounts payable
399	230	254	278	-37	593	522	-302	182	124	-45	-	117
Accrued and other current liabilities
376	-341	-922	-2,018	-8	1,635	-397	-717	1,444	35	-4,003	-1,711	451
Income taxes payable
-2,359	827	-3,291	124	-266	-21	-1,421	-34	-277	128	-365	-465	987
Noncurrent liabilities
-237	-266	-123	-809	-277	190	-132	-1,747	-7	-98	231	-108	26
Taxes paid for Internal Revenue Service settlement
-	-	-	-	-	-	-	-	-	-	-	-	-2,788
Net changes in assets and liabilities
32	674	1,087	-237	5	98	-563	1,203	262	160	-103	358	105
Net Cash Provided by Operating Activities
13,440	10,922	6,451	10,376	12,538	7,989	11,654	10,022	12,383	10,822	3,392	6,572	6,999
Cash Flows from Investing Activities
Capital expenditures
3,473	2,615	1,888	1,614	1,283	1,317	1,548	1,954	1,723	1,678	1,461	1,298	1,011
Purchases of securities and other investments
3,202	7,994	10,739	15,651	16,681	24,944	17,991	12,841	7,325	7,197	3,071	11,967	10,132
Proceeds from sales of securities and other investments
8,622	15,252	15,664	14,353	20,413	15,114	16,298	7,783	6,149	4,561	10,942	11,066	10,860
Proceeds from AstraZeneca option exercise
-	-	-	-	-	419	0	0	175	-	4,000	1,899	0
Acquisition of Antelliq Corporation, net of cash acquired
3,620	0	0	-	7,598	0	0	0	-	-	-	-	-
Acquisition of Peloton Therapeutics, Inc., net of cash acquired
1,040	0	0	-	-	3,700	0	-	-	-	-	-	-
Acquisition of ArQule, Inc., net of cash acquired
294	431	396	780	146	181	246	0	373	256	130	-	1,135
Divestiture of Merck Consumer Care business, net of cash divested
-	-	-	-	-	13,951	0	0	-	-	-	-	-
Dispositions of businesses, net of cash divested
-	-	-	-	316	1,169	46	0	323	-	-	-	-
Acquisition of Bayer AG collaboration rights
-	-	-	-	-	1,000	0	0	-	-	-	-	-
Cash inflows from net investment hedges
-	-	-	-	-	-195	-350	-39	86	-	-	-	-
Proceeds from sale of interest in Merial Limited
-	-	-	-	-	-	-	-	-	-	-	-	0
Schering-Plough merger, net of cash acquired
-	-	-	-	-	-	-	-	-	-	12,843	-	0
Proceeds from AstraZeneca LP asset option exercise
-	-	-	-	-	-	-	-	-	647	-	-	-
Decrease in restricted assets
-	-	-	-	-	-	-	-	-	-276	-5,548	-1,630	-1,401
Other
-378	-102	-38	-482	-221	80	57	-168	30	-150	-171	-96	-10
Net Cash (Used in) Provided by Investing Activities
-2,629	4,314	2,679	-3,210	-4,758	-374	-3,148	-6,805	-2,890	-3,497	3,156	-1,834	-2,810
Cash Flows from Financing Activities
Net change in short-term borrowings
-3,710	5,124	-26	0	-1,540	-460	-159	624	1,076	90	-2,422	1,860	11
Payments on debt
0	4,287	1,103	2,386	2,906	6,617	1,775	22	1,547	1,341	25	1,392	1,195
Proceeds from issuance of debt
4,958	0	0	1,079	7,938	3,146	6,467	2,562	0	1,999	4,228	-	0
Purchases of treasury stock
4,780	9,091	4,014	3,434	4,186	7,703	6,516	2,591	1,921	1,593	-	2,725	1,429
Dividends paid to stockholders
5,695	5,172	5,167	5,124	5,117	5,170	5,157	5,116	4,691	4,734	3,215	3,279	3,307
Other dividends paid
-	-	-	-	-	77	120	120	120	119	264	122	120
Proceeds from exercise of stock options
361	591	499	939	485	1,560	1,210	1,310	321	363	186	102	898
Other
5	-325	-195	-118	-61	79	60	86	-22	-106	-126	33	277
Net Cash Used in Financing Activities
-8,861	-13,160	-10,006	-9,044	-5,387	-15,242	-5,990	-3,267	-6,904	-5,441	-1,638	-5,523	-4,866
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
17	-205	457	-131	-1,310	-553	-346	-30	42	-295	33	-183	98
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash
1,967	1,871	-419	-2,009	1,083	-8,180	2,170	-80	2,631	1,589	4,943	-968	-578